Latest Tax Incentives News

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Entropy Neurodynamics has successfully enrolled and dosed the first patient in its pioneering clinical trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder, while securing $6.1 million in new funding to accelerate development.

Neurotech International has secured a Rare Pediatric Disease Designation from the FDA for its lead drug NTI164 targeting Rett syndrome, alongside publishing promising clinical data and raising $8.7 million to fuel further development.

Harvest Technology Group reports improved first-half FY26 financials alongside strategic defense sector expansions, including new reseller agreements and NATO engagements.

Iondrive Limited has marked a pivotal shift from development to commercialisation of its IONSolv™ technology, securing $4 million to target the US e-waste market and commissioning its pilot plant to refine critical minerals.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.

Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.

FBR Limited has set a new speed record with its Hadrian H04 bricklaying robot and secured its first binding sale of the Mantis welding robot, while advancing its partnership with Samsung Heavy Industries and navigating tight cash reserves.